Crossmark

Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01)

Crossref DOI link: https://doi.org/10.1245/s10434-026-19196-x

Published Online: 2026-02-28

Published Print: 2026-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yan, Ke

Wu, Zixiao

Liu, Xinyi

Liu, Yatian

Qian, Pudong

Gao, Min

Wang, Xiaobin

Guo, Xuehan

Shen, Wenbin
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct06828718 at ClinicalTrials.gov

Documents that mention this clinical trial

Safety and Survival Outcomes of Neoadjuvant Chemoradiotherapy Combined with Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter Real-World Analysis (NEO-EC-01)
https://doi.org/10.1245/s10434-026-19196-x
License Information

Text and Data Mining valid from 2026-02-28

Version of Record valid from 2026-02-28
More Information

Article History

Received: 12 September 2025

Accepted: 17 January 2026

First Online: 28 February 2026

Disclosure

: Ke Yan, Zixiao Wu, Xinyi Liu, Yatian Liu, Pudong Qian, Min Gao, Xiaobin Wang, Xuehan Guo, and Wenbin Shen declare no conflicts of interest that may be relevant to the contents of this study.

Document is current

Any future updates will be listed below